Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia

Atherosclerosis

Volumn 194, Issue 2, 2007, Pages 505-511

  Saito, Yasushi ^a   Yamada, Nobuhiro ^b   Shirai, Kohji ^c   Sasaki, Jun ^d   Ebihara, Yoshinori ^e   Yanase, Toshihiko ^f   Fox, Jonathan C ^g,h  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g ASTRAZENECA   (United Kingdom)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bezafibrate; Hypertriglyceridemia; Japanese; Lipoproteins; Rosuvastatin; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; JAPANESE; KIDNEY FUNCTION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS; BEZAFIBRATE; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; JAPAN; PYRIMIDINES; SULFONAMIDES; TRIGLYCERIDES;

EID: 34848822177     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.11.028     Document Type: Article

References (21)

1. Malloy M.J., and Kane J.P. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 47 (2001) 111-136
2. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86 9 (2000) 943-949
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III Final Report). JAMA 2001; 285 (19): 2486-97.
4. Stein E.A., Lane M., and Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 81 Suppl. 4A (1998) 66B-69B
5. Hunninghake D.B., Stein E.A., Bays H.E., et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 15 (2004) 115-123
6. Strutt K., Caplan R., Hutchison H., Dane A., and Blasetto J. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy. Circ J 68 (2004) 107-113
7. Saito Y., Goto Y., Dane A., et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 10 (2003) 329-336
8. Mabuchi H., Nohara A., Higashikata T., et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11 (2004) 152-158
9. The J-LAP Investigators. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 Report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: a study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res 66 (2005) 80-95
10. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
11. Robins S.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
12. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
13. Homma Y., Ozawa H., Kobayashi T., et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 106 (1994) 191-201
14. Ruotolo G., Ericsson C.G., Tettamanti C., et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
15. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
16. Cui Y., Blumenthal R.S., Flaws J.A., et al. Non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality. Arch Intern Med 161 (2001) 1413-1419
17. Frost P.H., and Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 81 Suppl. 4A (1998) 26B-31B
18. Sniderman A.D. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is .... Circulation 112 (2005) 3366-3367
19. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
20. Meisinger C., Loewel H., Mraz W., and Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 26 (2005) 271-278
21. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341